Skip to Main content Skip to Navigation
Journal articles

Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics

Abstract : For patients with metastatic pancreatic cancer that are not eligible for surgery, signal-targeted therapies have so far failed to significantly improve survival. These therapeutic options have been tested in phase II/III clinical trials mostly in combination with the reference treatment gemcitabine. Innovative therapies aim to annihilate oncogenic dependency, or to normalize the tumoural stroma to allow immune cells to function and/or re-vascularisation to occur. Large scale transcriptomic and genomic analysis revealed that pancreatic cancers display great heterogeneity but failed to clearly delineate specific oncogene dependency, besides oncogenic Kras. Beyond these approaches, proteomics appears to be an appropriate approach to classify signal dependency and to identify specific alterations at the targetable level. However, due to difficulties in sampling, proteomic data for this pathology are scarce. In this review, we will discuss the current state of clinical trials for targeted therapies against pancreatic cancer. We will then highlight the most recent proteomic data for pancreatic tumours and their metastasis, which could help to identify major oncogenic signalling dependencies, as well as provide future leads to explain why pancreatic tumours are intrinsically resistant to signal-targeted therapies. We will finally discuss how studies on phosphatidylinositol-3-kinase (PI3K) signalling, as the paradigmatic pro-tumoural signal downstream of oncogenic Kras in pancreatic cancer, would benefit from exploratory proteomics to increase the efficiency of targeted therapies.
Document type :
Journal articles
Complete list of metadata

Cited literature [94 references]  Display  Hide  Download

https://hal.archives-ouvertes.fr/hal-02500132
Contributor : Julie Guillermet-Guibert Connect in order to contact the contributor
Submitted on : Thursday, March 5, 2020 - 6:10:17 PM
Last modification on : Monday, June 14, 2021 - 11:42:03 AM
Long-term archiving on: : Saturday, June 6, 2020 - 4:50:45 PM

File

cancers-10-00174.pdf
Publisher files allowed on an open archive

Identifiers

Collections

Citation

Celia Cintas, Thibaut Douche, Nicole Therville, Silvia Arcucci, Fernanda Ramos-Delgado, et al.. Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics. Cancers, MDPI, 2018, 10 (6), pp.174. ⟨10.3390/cancers10060174⟩. ⟨hal-02500132⟩

Share

Metrics

Record views

117

Files downloads

345